Skip to content

Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder.

Gabrielle Agin-Liebes, Richard J. Zeifman, Jennifer Mitchell

European Journal of Psychotraumatology December 1, 2025 DOI: 10.1080/20008066.2025.2485513 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Secondary analysis of a randomized controlled trial Placebo-controlled Double-blind Peer reviewed
Sample size 82
Population Adults diagnosed with severe PTSD
Interventions MDMA-assisted therapy placebo plus therapy
Duration 18 weeks
Topics Depression MDMA Psychedelic-assisted therapy PTSD
Keywords MDMA-Assisted Therapy Self-compassion Autocompasión Depresión Posttraumatic stress disorder Mental health Trauma treatment
Citations 11
Key findings Changes in self-compassion fully mediated the effects of MDMA-assisted therapy compared to placebo plus therapy in reducing PTSD severity and depressive symptoms.

Abstract

Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcohol use disorder, and substance use disorders. A well-powered phase 3 randomized, placebo-controlled trial has shown that MDMA-assisted therapy (MDMA-AT) may be an effective treatment for severe PTSD. However, the psychological mechanisms driving the therapeutic effects of MDMA-AT remain unclear. One potential mechanism is self-compassion, which is commonly conceptualized as a balance between compassionate self-responding (CS) - encompassing self-kindness, common humanity, and mindfulness - and uncompassionate self-responding (UCS) - encompassing self-judgment, isolation, and over-identification.Objective: This secondary analysis aimed to explore whether MDMA-AT enhances aspects of self-compassion and if changes in self-compassion mediate the therapy's effectiveness in reducing PTSD severity, depressive, and alcohol and substance use symptoms.Method: Eighty-two adults diagnosed with severe PTSD participated in a double-blind trial comparing three sessions of either MDMA-AT or placebo combined with therapy. Measures of PTSD severity, depressive symptoms, alcohol and substance use, and self-compassion were collected at baseline and 18 weeks later.Results: MDMA-AT led to statistically significant improvements in both UCS and CS. Significant improvements were also observed across all six subscales of the Self-Compassion Scale, including self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification, most with large effect sizes. Changes in UCS and CS significantly and fully mediated the effects of MDMA-AT compared to placebo plus therapy in reducing PTSD severity and depressive symptoms. Findings were not significant for alcohol and substance use outcomes.Conclusions: These findings suggest that self-compassion may play a critical role in the therapeutic effects of MDMA-AT. Further research is needed to investigate the role of self-compassion in MDMA-AT to refine and develop more targeted, effective interventions for individuals with PTSD and co-occurring depression.

Comparable studies

Other randomized controlled trials on MDMA for depression, most cited first.

Study Year Design Participants
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. People with chronic posttraumatic stress disorder 2018 Randomized controlled trial n = 28
Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter Polydrug ecstasy users 2018 Pooled analysis of four placebo-controlled, within-subject studies n = 63
Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial. Participants with advanced-stage cancer and associated depression and anxiety 2024 Randomized controlled trial n = 32
MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder Adults with comorbid post-traumatic stress disorder and alcohol use disorder 2026 Randomized controlled trial n = 100

Citations in the library

Cited by 10

and 5 more in the library

Cites 13

and 8 more in the library

Related reading

Explore topics

Depression MDMA Psychedelic-assisted therapy PTSD Addiction Meditation

By condition and practice

MDMA and psychedelic-assisted therapy MDMA for PTSD MDMA for depression